In this episode, we introduce the rest of the Blue Ribbon Panel and interview our friends from NephMadness about their CAR-T region. Remember, RheumMadness brackets are open through March 31 at 11:59pm ET! Submit your brackets here. First time playing RheumMadness? Check out our new explainer video! Blue Ribbon Panelists in this episode: Anastasiya (Stacy) Bagrova, MD completed internal medicine residency at Duke, rheumatology fellowship at the University of South Florida, and is now a ...

In this episode, we introduce 2 of our fantastic Blue Ribbon Panel members. Their full bios are listed below. You'll meet the rest of the panel in the next episode! Also, RheumMadness brackets are open through March 31 at 11:59pm ET! Submit your brackets here. First time playing RheumMadness? Check out our new explainer video! Panelists in this podcast: Michele Meltzer, MD, MBE, is an Associate Professor of Medicine at Thomas Jefferson University in Philadelphia, Pennsylva...

In this episode we are joined by some amazing collaborators from the EMEUNET to talk about the STRAP trials. Links to the B-Cell Breakaway Scouting Reports: Obinutuzumab in lupus nephritis, by the University of Michigan Adult Rheumatology Fellowship ProgramCD-19 CAR T-cell therapy, by the Vanderbilt University Adult Rheumatology Fellowship ProgramSTRAP trial, by the Emerging EULAR Network (EMEUNET)Links to theMednet.org Q&As about this region: In the treatment of lupus nephritis, which pa...

In this episode we discuss obinutuzumab for lupus nephritis and anti-CD19 CAR T Cell therapy for autoimmune rheumatic disease. Links to the B-Cell Breakaway Scouting Reports: Obinutuzumab in lupus nephritis, by the University of Michigan Adult Rheumatology Fellowship ProgramCD-19 CAR T-cell therapy, by the Vanderbilt University Adult Rheumatology Fellowship ProgramSTRAP trial, by the Emerging EULAR Network (EMEUNET) Links to theMednet.org Q&As about this region: In the trea...

In this episode we present part 2 of our conversation about the teams in the Full Court Care Champions region of RheumMadness 2025! Links to the Full Court Care Champions Scouting Reports: Cost-effectiveness of hydroxychloroquine retinopathy screening, by residents from the Lankenau Medical Center Internal Medicine Residency ProgramSteroid dose in lupus nephritis, by the Washington University in St. Louis (WUSTL) Adult Rheumatology Fellowship ProgramSGCAPS prediction tool, by the Medical Co...

In this episode we dive into the teams in the Full Court Care Champions region of RheumMadness 2025! Links to the Full Court Care Champions Scouting Reports: Cost-effectiveness of hydroxychloroquine retinopathy screening, by residents from the Lankenau Medical Center Internal Medicine Residency ProgramSteroid dose in lupus nephritis, by the Washington University in St. Louis (WUSTL) Adult Rheumatology Fellowship ProgramSGCAPS prediction tool, by the Medical College of Wisconsin Adult Rheuma...

This episode contains part 2 of our conversation with Michael Macklin, MD, PharmD, Assistant Professor of Medicine at the University of Chicago, about the Cytokine Crushers region of RheumMadness 2025.In this episode, we focus specifically on the TYK2 in SLE and Oral Anti-IL23 teams. Links to the Cytokine Crushers Scouting Reports:Oral anti-IL23, by collaborating Chicago area rheumatology fellowship programs (Loyola, Northwestern, and the University of Chicago)Long-term outcomes of anifr...

In this episode, we are joined by Michael Macklin, MD, PharmD, Assistant Professor of Medicine at the University of Chicago, to discuss the teams in the Cytokine Crushers region of RheumMadness 2025, the Innovation Invitational.This is part 1 of the conversation, where we go in depth about the long-term outcomes of anifrolumab in SLE study and give a primer about type 1/2 cytokines so you're ready to dig into the TYK2 in SLE and Oral Anti-IL23 studies.Join us again next week for part 2 of thi...

In this episode, we present the second part of our conversation with the authors of the scouting reports for the teams in the T'd Up T-cells region of RheumMadness 2025: the Innovation Invitational. Plus, we highlight Q&As from theMednet.org about the T'd Up T-Cells teams AND record an interview with Dr. Bill St. Clair, the first author of the phase 2 dazodalibep study. It's a long episode because there's so much content!Links to the Q&As from theMednet.org discussed in th...

In this episode, we dive in to the T'd Up T-cells region of RheumMadness 2025: the Innovation Invitational. This is the first of a two-part conversation with the authors of the scouting reports for the teams in this region. Check back next week to hear the rest of the conversation!To find the scouting reports and base articles discussed in this episode, head over to the scouting reports page of our website here:https://sites.duke.edu/rheummadness/bracket-and-scouting-reports/ To l...